News

Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research

Orphazyme: NPC Community Notification

Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy

GAINESVILLE, FL–(Businesswire)–May 11, 2021–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, announced today it has appointed Lori McKenna Gorski as Global Head of Patient Advocacy...

ARDEnt publishes its findings on how the fragile rare disease ecosystem was disproportionately impacted by the COVID-19 pandemic

Today Action for Rare Disease Empowerment (ARDEnt) has published its findings andrecommendations in the report ‘Making The Unseen Seen: Rare disease and lessons learned from the COVID-19 pandemic’...

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on www.ClinicalTrials.gov and is preparing to commence its pivotal Phase 3 study evaluating Trappsol® Cyclo™...